Personalized DC Vaccine for Postoperative Cancer

The study is aimed to the test efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for postoperative locally advanced gastric cancer, hepatocellular carcinoma, lung cancer and colorectal cancer, and to explore the biomarkers related to efficacy and adverse event.

Trial Details

NCT ID

NCT04147078

Phase

PHASE1

Sponsor

Sichuan University

Status

RECRUITING

Cancer Type

Hepatocellular Carcinoma (HCC) Liver Cancer

Interventions

DC vaccine subcutaneous administration

Locations (sample)

Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

Participants with a first diagnosis of gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, colorectal cancer who have undergone a…
Anticipated life time \> 3month
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
Adequate organ functions

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →